Literature DB >> 16149130

Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma.

Wei-Hua Qiu1, Bing-Sen Zhou, Peiguo-G Chu, Wen-Gang Chen, Christopher Chung, Jennifer Shih, Paul Hwu, Christopher Yeh, Richard Lopez, Yun Yen.   

Abstract

AIM: To describe the significant over-expression of fibroblast growth factor receptor 3 (FGFR3), which is a signal transduction and cell proliferation related gene in hepatocellular carcinoma (HCC).
METHODS: Following DNA microarray, Northern blot and quantitative real-time PCR were employed to confirm FGFR3 expression difference in HCC tissues and surrounding non-neoplastic liver tissue. FGFR3 expression levels were further determined by immunohistochemical study in 43 cases of HCC.
RESULTS: Northern blot results showed the significant over-expression of FGFR3 in HCC tissues, which was consistent with that from DNA microarray. Quantitative real-time PCR demonstrated that the mean ratio of FGFR3 mRNA to glyceraldehyde-3-phosphate dehydrogenase (GADPH) mRNA in HCC tissue was 0.250, whereas the ratio in non-neoplastic liver tissue was 0.014. Statistical analyses of 43 cases of HCC revealed that HCC scored higher than the matched non-neoplastic liver tissues. Examination of clinicopathological features revealed a strong correlation of over-expression of FGFR3 with poor tumor differentiation and high nuclear grade.
CONCLUSION: Over-expression of FGFR3 may play an important role in liver carcinogenesis. FGFR3 may be an ideal candidate as a molecular marker in the diagnosis of HCC and a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16149130      PMCID: PMC4622793          DOI: 10.3748/wjg.v11.i34.5266

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein.

Authors:  M Kanai; M Göke; S Tsunekawa; D K Podolsky
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

Review 3.  The heparan sulfate-fibroblast growth factor family: diversity of structure and function.

Authors:  W L McKeehan; F Wang; M Kan
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1998

Review 4.  Microarray techniques in pathology: tool or toy?

Authors:  A M Snijders; G A Meijer; R H Brakenhoff; A J van den Brule; P J van Diest
Journal:  Mol Pathol       Date:  2000-12

5.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.

Authors:  C Billerey; D Chopin; M H Aubriot-Lorton; D Ricol; S Gil Diez de Medina; B Van Rhijn; M P Bralet; M A Lefrere-Belda; J B Lahaye; C C Abbou; J Bonaventure; E S Zafrani; T van der Kwast; J P Thiery; F Radvanyi
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

6.  Estimates of the worldwide incidence of 25 major cancers in 1990.

Authors:  D M Parkin; P Pisani; J Ferlay
Journal:  Int J Cancer       Date:  1999-03-15       Impact factor: 7.396

7.  Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer.

Authors:  J H Jang; K H Shin; Y J Park; R J Lee; W L McKeehan; J G Park
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

8.  Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.

Authors:  M C Naski; Q Wang; J Xu; D M Ornitz
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

9.  BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers.

Authors:  J Adnane; P Gaudray; C A Dionne; G Crumley; M Jaye; J Schlessinger; P Jeanteur; D Birnbaum; C Theillet
Journal:  Oncogene       Date:  1991-04       Impact factor: 9.867

10.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

View more
  22 in total

1.  DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma.

Authors:  Guiji Zhang; Xia Tang; Li Liang; Wanfeng Zhang; Dewei Li; Xiaoyuan Li; Dachun Zhao; Yaqiu Zheng; Yanhong Chen; Bingtao Hao; Kai Wang; Ni Tang; Keyue Ding
Journal:  Oncogene       Date:  2020-02-19       Impact factor: 9.867

2.  Investigation on correlation between expression of CD58 molecule and severity of hepatitis B.

Authors:  Li Sheng; Jie Li; Bao-Tai Qi; Yu-Qiang Ji; Zhao-Jun Meng; Ming Xie
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

3.  Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma.

Authors:  Shi Liu; Jian Gong; Asahiro Morishita; Takako Nomura; Hisaaki Miyoshi; Joji Tani; Kiyohito Kato; Hirohito Yoneyama; Akihiro Deguchi; Hirohito Mori; Shima Mimura; Kei Nomura; Takashi Himoto; Kazushi Deguchi; Keiichi Okano; Kunihiko Izuishi; Yasuyuki Suzuki; Yoshio Kushida; Reiji Haba; Hisakazu Iwama; Tsutomu Masaki
Journal:  Exp Ther Med       Date:  2011-02-08       Impact factor: 2.447

4.  Mutation Detection of Fibroblast Growth Factor Receptor 3 for Infiltrative Hepatocellular Carcinoma by Whole-Exome Sequencing.

Authors:  Xiaopeng Yan; Cong Shao; Chuang Chen; Jun Chen; Shen Gu; Luoshun Huang; Xu Fu; Hui Zhao; Yudong Qiu
Journal:  Dig Dis Sci       Date:  2017-01-05       Impact factor: 3.199

Review 5.  Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.

Authors:  Jaleh Varshosaz; Maryam Farzan
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

6.  Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

Authors:  Jing Qing; Xiangnan Du; Yongmei Chen; Pamela Chan; Hao Li; Ping Wu; Scot Marsters; Scott Stawicki; Janet Tien; Klara Totpal; Sarajane Ross; Susanna Stinson; David Dornan; Dorothy French; Qian-Rena Wang; Jean-Philippe Stephan; Yan Wu; Christian Wiesmann; Avi Ashkenazi
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

7.  Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis.

Authors:  Natacha Entz-Werle; Thomas Lavaux; Nadia Metzger; Corinne Stoetzel; Christelle Lasthaus; Perrine Marec; Chantal Kalifa; Laurence Brugieres; Hélène Pacquement; Claudine Schmitt; Marie-Dominique Tabone; Jean-Claude Gentet; Patrick Lutz; Annie Babin; Pierre Oudet; Marie Pierre Gaub; Fabienne Perrin-Schmitt
Journal:  Neoplasia       Date:  2007-08       Impact factor: 5.715

Review 8.  Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease.

Authors:  Mark A Feitelson; Helena M G P V Reis; N Lale Tufan; Bill Sun; Jingbo Pan; Zhaorui Lian
Journal:  Cancer Lett       Date:  2009-02-06       Impact factor: 8.679

9.  Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer.

Authors:  Hideaki Murase; Mikito Inokuchi; Yoko Takagi; Keiji Kato; Kazuyuki Kojima; Kenichi Sugihara
Journal:  Mol Clin Oncol       Date:  2014-05-15

10.  FGFR3 promotes angiogenesis-dependent metastasis of hepatocellular carcinoma via facilitating MCP-1-mediated vascular formation.

Authors:  Xinyu Liu; Xiaoqian Jing; Xi Cheng; Ding Ma; Zhijian Jin; Weiping Yang; Weihua Qiu
Journal:  Med Oncol       Date:  2016-04-04       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.